| 2023-GHOS-70150 | |
| Researchers at Purdue have developed a novel series of compounds using structure-based design that show significant inhibition of HIV-1 protease. Current anti-retroviral drugs are contending with new drug-resistant strains of HIV-AIDS and have several major side effects associated with the cardiovascular and central nervous system. In order to provide new treatment options, researchers have developed a series of novel compounds by maximizing hydrogen bonding interactions with the active site protease backbone atoms. The series of compounds made by researchers at Purdue incorporated derivatives of nilotinib-like pyridyl pyrimidinyl groups and thiazole heterocycles in combination with the hydroxyethylamine sulfonamide isostere group of the HIV-1 protease inhibitor darunavir. The researchers tested the enzyme inhibitory ability and the IC50 of each molecule and found that several had inhibitory activity at the nanomolar and sub-nanomolar level as well as antiviral activity at the low nanomolar level. Technology Validation: - Enzyme inhibitory activity of molecules verified through an enzyme-inhibitory assay with HIV protease. - Antiviral activity of molecules validated with MT-2 human-T-lymphoid cells model with HIVLAI. Advantages: - Select compounds among series have better and/or comparable antiviral and enzyme inhibitory activity of HIV and HIV-1 protease. - Distinct chemical structure from other commercial HIV protease inhibitors, potentially more difficult for new strains to develop resistance to new series of compounds. Applications: - HIV/AIDS treatment: New series of compounds could be developed into anti-retroviral drugs against multi-drug resistant strains of HIV. - HIV/AIDS diagnostics: Fluorophores could be bound to compounds and be used to visualize distribution of HIV-1 protease within cells. |
|
|
|
|
Mar 24, 2023
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
